Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017
The gabapentinoid drugs gabapentin and pregabalin are approved for epilepsy, neuropathic pain, migraines (gabapentin only), and generalized anxiety disorders (pregabalin only) in the United Kingdom. These indications differ in other countries. Gabapentinoid prescriptions increased in the United States between 2002 and 2015, 1 which may be partly related to an increase in off-label use. 2 These medications have the potential for misuse and addiction and for overdose, when used in combination with opioids. 3 In 2017, the UK government reclassified gabapentinoids as class C controlled substances. 4 We estimated the rates of patients treated with gabapentin and pregabalin for the first time in the UK primary care system since these drugs were first licensed in 1993 and 2004, respectively.
Methods | Using the Clinical Practice Research Datalink (CPRD), a UK database of primary care medical records from more than 15 million patients, 5 we identified all patients registered for at least 1 day between 1993 and 2017, with follow-up starting on January 1, 1993, or the patient's registration date with the practice, whichever came later. Follow-up ended at the date the patient transferred out of the practice, the date of the patient's death, or December 31, 2017, whichever occurred first. We used Poisson regression to estimate the annual rates of patients newly treated with gabapentin and pregabalin, separately, estimating rate ratios (RRs) over the last 10 years. For each patient with a first prescription, we identified same-day prescriptions for opiates and/or benzodiazepines (including sedatives). We inferred the indication corresponding to their first prescription using relevant diagnostic codes up to 1 year before this first prescription. Indication was classified in a hierarchical manner into 1 of 3 mutually exclusive categories: approved, off-label (nonneuropathic pain, other), or unknown. The study protocol was approved by the Independent Scientific Advisory Committee of the CPRD and the research ethics committee of the Jewish General Hospital, which also waived the need for patient informed consent. All analyses were conducted with SAS, version 9.4 (SAS Institute Inc). We identified a prescription indication for 64.2% of patients newly treated with gabapentin and 63.2% of patients newly treated with pregabalin. The rate of patients with an offlabel indication increased from 58.7 to 216.0 per 100 000 persons per year for gabapentin (RR, 3.68 [95% CI, 3.52-3.85]) and from 34.7 to 117.8 per 100 000 persons per year for pregabalin (RR, 3.40 [95% CI, 3.20-3.60]) ( Figure 2 ). Off-label prescriptions accounted for 52.0% of gabapentin and 54.8% of pregabalin prescriptions with an identified indication in 2017. Nonneuropathic pain accounted for 80.4% of gabapentin and 58.3% of pregabalin off-label prescriptions.
Results
Discussion | The rate of patients newly treated with gabapentinoids has tripled from 2007 to 2017 in primary care in the United Kingdom. By 2017, 50% of gabapentinoid prescriptions were for an off-label indication and 20% had a coprescription for opioids.
The study had some limitations. Prescription indications were inferred from patients' medical history. An indication was identified for 60% of all patients newly treated because indications are not systematically recorded in the CPRD for each issued prescription, which could lead to misclassification. Also, only primary care practices were included. However, as general practitioners are central to the UK health system, most gabapentinoid prescriptions were likely issued by general practitioners, even when the treatment was initiated by a specialist. To the Editor In an extended follow-up of the Escitalopram for Depression in Acute Coronary Syndrome (EsDEPACS) trial, Dr Kim and colleagues randomized 300 patients with recent acute coronary syndrome (ACS) and major or minor depression to receive 24 weeks of escitalopram (n = 149) or placebo (n = 151) and reported significantly fewer major adverse cardiac events (MACE) a median of 8.1 years later in the escitalopram group. 1 As noted by the authors, previous trials have not observed similar reductions in cardiac events or mortality. Kim and colleagues offered several possible explanations for these divergent findings, but several additional issues merit consideration. First, selective reporting of outcome analyses and description of post hoc analyses as planned analyses increase the risk of publishing false-positive findings. 2 Neither the ClinicalTrials.gov registration record of the EsDEPACS trial nor previously published 1-year trial results described any cardiovascular outcomes. 3 Moreover, MACE is not consistently defined across studies, and different definitions can lead to different results. 4 Because MACE was not mentioned in the EsDEPACS registration and because no protocol was publicly available prior to publication of results, MACE may not have been a predefined outcome, and there was no public documentation that the components of MACE were defined prior to data analysis. Second, the reported effect of escitalopram treatment on MACE was large compared with the effect on depression. There were 20 more MACE events in the placebo group (n = 81) than the escitalopram group (n = 61), even though only 19 more patients in the escitalopram group (n = 57) achieved remission of their depression compared with placebo patients (n = 38).
Third, as shown in Figure 2 in the article, at 1 year after randomization, cumulative MACE incidence was approximately 10% in both the escitalopram and placebo groups, and cumulative incidence curves began to diverge only subsequently. Mean length of depression treatment in the trial was only 4.5 months, 4 and at 1 year after randomization only 5 patients randomized to escitalopram and 3 randomized to placebo were taking antidepressants. Thus, differences in MACE incidence began to emerge long after most patients in the trial had discontinued antidepressant use. This raises questions about the potential mechanism and biological plausibility of the findings. We believe that these issues emphasize the need for cautious interpretation of results and for replication. First, the cumulative event curves of the primary outcome ( Figure 2 in the article) appear to be created inappropriately. Normally, vertical steps in a Kaplan-Meier curve represent events. 2, 3 However, in this figure, there is a mismatch between the number of events and vertical steps. For example, the escitalopram curve has visually more than 100 steps, while the text only reported 61 MACE events in this group. This mismatch is present in the opposite direction for the placebo curve, having fewer steps than reported events. What is the reason for this mismatch and does it have an effect on the analysis of the primary end point? Second, the numbers at risk presented below the cumulative event curves (Figure 2 and Figure 3 in the article) seem to be incorrect. The numbers at risk appear to be reduced only by events and not by loss to follow-up. Because the median follow-up of the study was 8.1 years and the figures showed up to 12 years of follow-up, more censoring is expected than presented.
Third, the protocol synopsis, provided in Supplement 1 of the article, stated that cardiac death was a component of the 
